Cargando…
Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer
Background: Pembrolizumab monotherapy or pembrolizumab plus chemotherapy has become an important frontline treatment for advanced non-small cell lung cancer (NSCLC). To date, it remains unclear how the coronavirus disease 2019 (COVID-19) pandemic impacted the treatment outcome. Methods: A quasi-expe...
Autores principales: | Tanvetyanon, Tawee, Chen, Dung-Tsa, Gray, Jhanelle E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960275/ https://www.ncbi.nlm.nih.gov/pubmed/36836146 http://dx.doi.org/10.3390/jcm12041611 |
Ejemplares similares
-
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
por: Chiappori, Alberto A., et al.
Publicado: (2018) -
Impact of Robotic-Assisted Thoracic Surgery on the Completion of Adjuvant Chemotherapy Following Lung Cancer Resection
por: Abdelghany, Khaled, et al.
Publicado: (2022) -
Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report
por: Ahmad, Yaser, et al.
Publicado: (2023) -
Emerging Approaches to Complement Low-Dose Computerized Tomography for Lung Cancer Screening: A Narrative Review
por: Maller, Bradley, et al.
Publicado: (2022) -
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Chen, Dung-Tsa, et al.
Publicado: (2023)